{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:07:07Z","timestamp":1792688827420,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.revmed.2025.03.424","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:19:22Z","timestamp":1746443962000},"page":"287-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of real-world data for the development and the follow-up of drugs in rare diseases. The example of immune thrombocytopenia and autoimmune hemolytic anemia"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9953-4640","authenticated-orcid":false,"given":"Guillaume","family":"Moulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3420-7005","authenticated-orcid":false,"given":"Yoann","family":"Zadro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2025.03.424_bib0305","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.3390\/ijerph191610159","article-title":"Real-world evidence-current developments and perspectives","volume":"19","author":"Schad","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.revmed.2025.03.424_bib0310","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharm Med"},{"key":"10.1016\/j.revmed.2025.03.424_bib0315","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/pds.5222","article-title":"Real-world evidence to support regulatory decision making: new or expanded medical product indications","volume":"30","author":"Franklin","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.revmed.2025.03.424_bib0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.revmed.2020.05.018","article-title":"New insights into the epidemiology of immune thrombocytopenia in adult patients: impact for clinical practice","volume":"42","author":"Moulis","year":"2021","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2025.03.424_bib0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.therap.2018.12.009","article-title":"Pharmacoepidemiology, the new paradigm of drug evaluation","volume":"74","author":"B\u00e9gaud","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.revmed.2025.03.424_bib0330","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.therap.2020.02.013","article-title":"The challenges of pharmacoepidemiology of orphan drugs in rare diseases","volume":"75","author":"Lapeyre-Mestre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.revmed.2025.03.424_bib0335","unstructured":"Shuren J. Leveraging Real World Evidence in Regulatory Submissions of Medical Devices 2021. Available at: https:\/\/www.fda.gov\/news-events\/fda-voices\/leveraging-real-world-evidence-regulatory-submissions-medical-devices. Accessed on July 10, 2024."},{"key":"10.1016\/j.revmed.2025.03.424_bib0340","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pds.4962","article-title":"Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions","volume":"29","author":"Wu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.revmed.2025.03.424_bib0345","doi-asserted-by":"crossref","first-page":"1236462","DOI":"10.3389\/fmed.2023.1236462","article-title":"Real-world evidence for regulatory decision-making: updated guidance from around the world","volume":"10","author":"Burns","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.revmed.2025.03.424_bib0350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-024-03111-2","article-title":"A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases","volume":"19","author":"Vaghela","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2025.03.424_bib0355","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/14740338.2019.1614165","article-title":"Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study","volume":"18","author":"Crisafulli","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.revmed.2025.03.424_bib0360","first-page":"263","article-title":"Pharmacoepidemiology: definition, methods and applications","volume":"199","author":"Montastruc","year":"2015","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.revmed.2025.03.424_bib0365","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.18111","article-title":"Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network","volume":"197","author":"Moulis","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0370","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.revmed.2024.06.006","article-title":"CARMEN-France investigators group, Collaborators (the CARMEN-France investigators group). The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France","volume":"45","author":"Moulis","year":"2024","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2025.03.424_bib0375","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26683","article-title":"Reliable assessment of the incidence of childhood autoimmune hemolytic anemia","volume":"64","author":"Aladjidi","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.revmed.2025.03.424_bib0380","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/ajh.25574","article-title":"Evans syndrome in adults - incidence, prevalence, and survival in a nationwide cohort","volume":"94","author":"Hansen","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0385","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/CLEP.S250250","article-title":"Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980-2016","volume":"12","author":"Hansen","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0390","doi-asserted-by":"crossref","first-page":"E262","DOI":"10.1002\/ajh.26196","article-title":"Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy","volume":"96","author":"Hansen","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0395","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2025.03.424_bib0400","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.1002\/ajh.26213","article-title":"Epidemiology of autoimmune hemolytic anemia: a nationwide population-based study in France","volume":"96","author":"Maquet","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0405","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/14740338.2023.2219892","article-title":"An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting","volume":"22","author":"Crisafulli","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.revmed.2025.03.424_bib0410","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/bjh.19742","article-title":"The powers and perils of large language models in haematology","volume":"205","author":"Glass","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0415","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.revmed.2025.03.424_bib0420","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.therap.2023.01.009","article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice","volume":"78","author":"de Germay","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.revmed.2025.03.424_bib0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2024.05.003","article-title":"Use of the French National Health Data System (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase","author":"Maillard","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.revmed.2025.03.424_bib0430","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjh.19242","article-title":"Primary autoimmune haemolytic anaemia is associated with increased risk of ischaemic stroke: a binational cohort study from Denmark and France","volume":"204","author":"Hansen","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0435","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.13385","article-title":"Fatigue in immune thrombocytopenia","volume":"170","author":"Hill","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0440","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PROM.S140932","article-title":"Immune thrombocytopenia: improving quality of life and patient outcomes","volume":"9","author":"Trotter","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.revmed.2025.03.424_bib0445","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.17694","article-title":"Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI)","volume":"194","author":"Cooper","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0450","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajh.26045","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0455","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0460","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.13984","article-title":"Development of the Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD-SIQ)","volume":"111","author":"Joly","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0465","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/ajh.27298","article-title":"Bleeding self-assessments by patients with immune thrombocytopenia (ITP): an agreement study","volume":"99","author":"Clerici","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0470","unstructured":"World Health Organization Uppsala Monitoring Centre. Pharmacovigilance: ensuring the safe use of medicines - WHO Policy Perspectives on Medicines. Available at: https:\/\/iris.who.int\/bitstream\/handle\/10665\/68782\/WHO_EDM_2004.8.pdf. Accessed July 10, 2024."},{"key":"10.1016\/j.revmed.2025.03.424_bib0475","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0480","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/bloodadvances.2023009801","article-title":"Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study","volume":"8","author":"Maquet","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2025.03.424_bib0485","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamainternmed.2021.8523","article-title":"Risk of immune thrombocytopenia after influenza vaccine","volume":"182","author":"Lafaurie","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.revmed.2025.03.424_bib0490","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.19075","article-title":"Refractory immune thrombocytopenia in adults: towards a new definition","volume":"203","author":"Arnold","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0495","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/bjh.19288","article-title":"Difficult-to-treat primary immune thrombocytopenia in adults: prevalence and burden.\u00a0Results from the CARMEN-France registry","volume":"204","author":"Moulis","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0500","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jth.14446","article-title":"Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia","volume":"17","author":"Adelborg","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2025.03.424_bib0505","doi-asserted-by":"crossref","first-page":"E181","DOI":"10.1002\/ajh.25127","article-title":"Cardiovascular risk factors in immune thrombocytopenia adults: results from the CARMEN registry","volume":"93","author":"Moulis","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0510","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bjh.17709","article-title":"Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study","volume":"195","author":"Lafaurie","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0515","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.17390","article-title":"Thrombosis in immune thrombocytopenia - current status and future perspectives","volume":"194","author":"Swan","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0520","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/bjh.19327","article-title":"The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim","volume":"204","author":"Al-Samkari","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0525","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.revmed.2025.03.424_bib0530","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJMp2401487","article-title":"Four decades of orphan drugs and priorities for the future","volume":"391","author":"Sinha","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.03.424_bib0535","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2025.03.424_bib0540","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000533175","article-title":"Fostamatinib or Thrombopoietin for the treatment of chronic immune thrombocytopenia in adult patients: a real-world assessment of safety, effectiveness and cost","volume":"147","author":"Dranitsaris","year":"2024","journal-title":"Acta Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0545","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/ajh.27358","article-title":"Cost-effectiveness of sutimlimab in cold agglutinin disease","volume":"99","author":"Ito","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0550","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0555","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2025.03.424_bib0560","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2025.03.424_bib0565","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2025.03.424_bib0570","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0575","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.revmed.2016.09.016","article-title":"[Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]","volume":"38","author":"Weber","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2025.03.424_bib0580","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2025.03.424_bib0585","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1111\/bjh.16561","article-title":"No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study","volume":"189","author":"Lafaurie","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0590","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.26404","article-title":"Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: the multicenter, prospective ELEXTRA study","volume":"97","author":"Moulis","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2025.03.424_bib0595","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/bloodadvances.2024014939","article-title":"Efficacy and safety of dapsone in primary immune thrombocytopenia. Results of a randomized, placebo-controlled multicenter trial and of a single-arm, emulated trial in the prospective, multicenter Carmen-France Registry","volume":"9","author":"Larue","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2025.03.424_bib0600","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMra2212850","article-title":"Where medical statistics meets artificial intelligence","volume":"389","author":"Hunter","year":"2023","journal-title":"N Engl J Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325005053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325005053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T14:39:40Z","timestamp":1747319980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866325005053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0248866325005053"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2025.03.424","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of real-world data for the development and the follow-up of drugs in rare diseases. The example of immune thrombocytopenia and autoimmune hemolytic anemia","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2025.03.424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}